Konfer Launches DORA Compliance Controls Catalog to Help EU Meet January 2025 Compliance Deadline, Partners With Leading Law Firm Osborne Clarke to Offer DORA Compliance Check to EU Organizations
10.9.2024 10:00:00 CEST | Business Wire | Press release
Konfer, the Silicon Valley-based Agentic AI product company, today announced the launch of the Konfer DORA Compliance Controls Catalog to help EU financial institutions meet the January 2025 conformance deadline.
The Konfer DORA Control Questions Catalog is designed to guide financial institutions through the complexities of the Digital Operational Resilience Act (DORA). Konfer’s AI agent has interpreted DORA’s extensive regulation, converting the obligations into practical control questions. These questions not only assess compliance but also integrate team responses to provide a detailed view of an organization's operational resilience, identifying potential vulnerabilities, and enhancing risk management processes.
“The Konfer DORA Controls Catalog was designed to help EU financial institutions not just get a translation of the DORA compliance, but to actively implement the controls across their teams and operationalize compliance,” said Debu Chatterjee, CEO of Konfer. “It takes out guess-work or interpretation gaps, and empowers ICT and compliance leaders with a rubric for conformance, with the shortest time-to-value, given the approaching January 2025 deadline.”
IT leaders and Compliance executives in the EU financial institutions are required to specify the elements which a financial entity needs to determine and assess when subcontracting ICT services supporting critical or important functions. This puts the burden of collecting responses from third party vendors, analyzing the responses, and identify vulnerabilities on the financial institution. “With Konfer Clear for DORA, executive leadership can now gain complete visibility into their third-party vendors’ compliance, and proactively require them to upgrade and maintain their resiliency,” continued Chatterjee. “Our focus is to help operationalize compliance—whether internally or with external vendors—so that the compliance teams are able to focus on risk analysis, vulnerability assessments, and proactive remediation rather than on repetitive tasks.”
Konfer has partnered with leading law firm Osborne Clarke Netherlands to develop DORA Compliance Check for the firm’s clients. The law firm will leverage Konfer Clear to provide clients with advice on their DORA Compliance requirements, gaps, and confidence score.
“We are pleased to partner with Konfer, and look forward to enabling our clients to accelerate their DORA compliance time-to-completion, using Konfer Clear,” said Johannes de Jong, Financial Regulatory partner at Osborne Clarke Netherlands. “This online tool will help our clients to rapidly upload their compliance documents and receive a Clear scorecard, thereby providing valuable insights for their ICT contract management.”
Konfer DORA Compliance Controls is easily embedded into workflows, and is able to connect with the financial institutions internal and external ICT systems. The AI-powered suite is able to rapidly analyze gaps, compare with any new updates to the compliance mandates, and alert IT and compliance leaders.
The DORA Compliance Controls can be downloaded from https://konfer.ai/acts/finance/
About Konfer: Based in Milpitas, CA, Konfer is a venture-backed Agentic AI product that delivers governance workflows to manage the explosion of regulations across the world in a standard scalable way.
About Osborne Clarke: Osborne Clarke is an international, full-service law firm with over 330 partners and more than 1,630 legal experts working across 26 global locations. We combine the personalised service of a local office with the resources and reach of a large international firm, providing effective solutions for complex issues. Osborne Clarke has an impressive client base in the sectors of Energy & Utilities, Financial Services, Life Sciences & Healthcare, Mobility & Infrastructure, Retail & Consumer, Tech, Media & Comms, The Built Environment, and Workforce Solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910605198/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom